Add your support for the PBS listing of Epidyolex (cannabidiol) for the treatment of TSC-related seizures

Our friends at Jazz Pharmaceuticals have submitted applications to the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Advisory Committee (PBAC) to get Epidyolex® (cannabidiol) approved for the treatment of seizures associated with TSC.

The PBAC will consider the application for PBS listing at its November 2026 meeting. Now is the time to show your support.

Public comments are an important part of the PBAC decision-making process. Your input can help the PBAC better understand the potential benefits of improved access to Epidyolex for people living with TSC, as well as the impact this may have on families, carers and the health care professionals who support them.

Please click HERE to complete a short survey and show your support.

The public consultation period is open until 16 September 2026.